- Home
- RBOT vs BCAB Comparison
RBOT vs BCAB Comparison
Compare RBOT & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- BCAB
- Stock Information
- Founded
- RBOT 2014
- BCAB 2007
- Country
- RBOT United States
- BCAB United States
- Employees
- RBOT N/A
- BCAB N/A
- Industry
- RBOT Medical Specialities
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- RBOT Health Care
- BCAB Health Care
- Exchange
- RBOT Nasdaq
- BCAB Nasdaq
- Market Cap
- RBOT 94.2M
- BCAB 77.8M
- IPO Year
- RBOT N/A
- BCAB 2020
- Fundamental
- Price
- RBOT $12.99
- BCAB $1.29
- Analyst Decision
- RBOT Hold
- BCAB Buy
- Analyst Count
- RBOT 2
- BCAB 2
- Target Price
- RBOT $10.25
- BCAB $5.00
- AVG Volume (30 Days)
- RBOT 53.0K
- BCAB 645.3K
- Earning Date
- RBOT 11-12-2024
- BCAB 11-07-2024
- Dividend Yield
- RBOT N/A
- BCAB N/A
- EPS Growth
- RBOT N/A
- BCAB N/A
- EPS
- RBOT N/A
- BCAB N/A
- Revenue
- RBOT N/A
- BCAB $11,000,000.00
- Revenue This Year
- RBOT N/A
- BCAB N/A
- Revenue Next Year
- RBOT N/A
- BCAB N/A
- P/E Ratio
- RBOT N/A
- BCAB N/A
- Revenue Growth
- RBOT N/A
- BCAB N/A
- 52 Week Low
- RBOT $4.27
- BCAB $1.14
- 52 Week High
- RBOT $21.42
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- RBOT 55.36
- BCAB 33.19
- Support Level
- RBOT $12.53
- BCAB $1.28
- Resistance Level
- RBOT $16.55
- BCAB $1.72
- Average True Range (ATR)
- RBOT 1.89
- BCAB 0.10
- MACD
- RBOT -0.29
- BCAB -0.02
- Stochastic Oscillator
- RBOT 26.25
- BCAB 4.35
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.